Results

1–4 of 4 results for Good Days

Changes in Retinal Disease Treatment Patterns Due to Copay Assistance Loss A Real-World Multi-Indication Analysis Using Vestrum Retinal Health Database
Ghassan Ghorayeb, MD
Annual Meeting Talks
2025
The Impact of Good Days' Underfunding on Retinal Disease Management Insights From a National Survey of American Society of Retina Specialists Members
Michael M. Lai, MD, PhD
Annual Meeting Talks
2025
Evaluating the Visual, Anatomic, and Treatment Effects of Switching from Higher-cost Anti-VEGF to Lower-cost Bevacizumab After Loss of Copay Assistance (Good Days) Funding in Neovascular Age-Related Macular Degeneration
Jesse J Jung, MD, FASRS
Updates from the Field
2026
Impact of Loss of Good Days Copay Assistance Program on Clinical and Anatomical Outcomes of Retinal Disease
Danny A. Mammo, MD
Updates from the Field
2026